Qualigen Therapeutics Inc
NASDAQ:QLGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Qualigen Therapeutics Inc
NASDAQ:QLGN
|
US |
|
B
|
Boombit SA
WSE:BBT
|
PL |
|
W
|
WA1 Resources Ltd
ASX:WA1
|
AU |
|
Suzhou Alton Electrical & Mechanical Industry Co Ltd
SZSE:301187
|
CN |
|
A
|
Alpha Copper Corp
CNSX:ALCU
|
CA |
|
Digispice Technologies Ltd
NSE:DIGISPICE
|
IN |
|
R
|
Revo Insurance SpA
MIL:REVO
|
IT |
|
Mic AG
XETRA:M3BK
|
DE |
|
P
|
Pacifico Renewables Yield AG
XETRA:PRY
|
DE |
|
O
|
Ober SA
PAR:ALOBR
|
FR |
|
G
|
GuangDong Rifeng Electric Cable Co Ltd
SZSE:002953
|
CN |
|
Hainan RuiZe New Building Material Co Ltd
SZSE:002596
|
CN |
|
S
|
Shenzhen XFH Technology Co Ltd
SZSE:300890
|
CN |
|
China Merchants Port Group Co Ltd
SZSE:001872
|
CN |
|
F
|
Fluence Corporation Ltd
F:4SVE
|
US |
Qualigen Therapeutics Inc
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company is headquartered in Los Angeles, California and currently employs 39 full-time employees. The company went IPO on 2015-06-24. The firm's cancer therapeutics pipeline includes QN-302, QN-247 and RAS-F. QN-302 compound is a small molecule genomic quadruplex (G4) selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. RAS-F is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins and preventing this binding to stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers. Its pipeline also includes QN-165, a drug candidate for treating COVID-19 and other viral-based infectious diseases.
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company is headquartered in Los Angeles, California and currently employs 39 full-time employees. The company went IPO on 2015-06-24. The firm's cancer therapeutics pipeline includes QN-302, QN-247 and RAS-F. QN-302 compound is a small molecule genomic quadruplex (G4) selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. RAS-F is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins and preventing this binding to stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers. Its pipeline also includes QN-165, a drug candidate for treating COVID-19 and other viral-based infectious diseases.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
